Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art.

Cells - 6 Jan 2020

Smorodinsky-Atias Karina, Soudah Nadine, Engelberg David

Abstract excerpt

Unique characteristics distinguish extracellular signal-regulated kinases (Erks) from other eukaryotic protein kinases (ePKs). Unlike most ePKs, Erks do not autoactivate and they manifest no basal activity; they become catalysts only when dually phosphorylated on neighboring Thr and Tyr residues and they possess unique structural motifs. Erks function as the sole targets of the receptor tyrosine kinases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Evolution
Share to Carcinogenesis
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Melanoma and MAPK Pathways

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Synthesis and biological activity

Source

Open in PubMed Open full text

Identifiers

PMID: 31935908
DOI: 10.3390/cells9010129
PMCID: PMC7016714

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art.PMID 31935908Read ↗

Targeting pathological ERK1/2 signaling in cancer and beyondSemantic proximity Read ↗

Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.Semantic proximity Read ↗

Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancerSemantic proximity Read ↗

A conserved arginine within the αC-helix of Erk1/2 is a latch of autoactivation and of oncogenic capabilities.Semantic proximity Read ↗

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity Read ↗

The MEK/ERK Network as a Therapeutic Target in Human CancerSemantic proximity Read ↗

ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.Semantic proximity Read ↗

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKSemantic proximity Read ↗

Isolation of intrinsically active (MEK-independent) variants of the ERK family of mitogen-activated protein (MAP) kinases.Semantic proximity Read ↗

The Landscape of Atypical and Eukaryotic Protein Kinases.Semantic proximity Read ↗

Oncogenic signaling of MEK5-ERK5.Semantic proximity Read ↗

Deciphering the RAS/ERK pathway in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.